INVA

Innoviva Inc

21.28

Oct 20 • 3:59 PM ET +0.20 (0.95%)

21.28

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: LGND RPRX HRMY ADMA MIRM PCRX GSK SPRO HRTX EBS

| Held by: IJR VTI IWM VB DFSV DFAT VBR PJP VXF IWN

Scroll to Statements

Index	RUT
Market Cap	1.54B
Enterprise Value	1.23B
Income	357.24M
Sales	453.80M
Book/sh	16.98
Cash/sh	8.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Sep 08, 2015
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	159
IPO	Oct 05, 2004

P/E	5.18
Forward P/E	9.41
PEG	-
P/S	3.39
P/B	1.25
P/C	2.65
P/FCF	8.12
EV/EBITDA	6.05
EV/Sales	2.71
Quick Ratio	15.18
Current Ratio	16.01
Debt/Eq	0.22
LT Debt/Eq	0.22
Option/Short	Yes / Yes

EPS (ttm)	4.10
EPS next Y	2.26
EPS next Q	0.52
EPS this Y	-26.67%
EPS next Y	-6.53%
EPS next 5Y	-15.80%
EPS past 3/5Y	- 10.35%
Sales past 3/5Y	325.77% 3.93%
EPS Y/Y TTM	693.83%
Sales Y/Y TTM	18.17%
EPS Q/Q	-247.04%
Sales Q/Q	18.61%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-361.47% 7.75%

Insider Own	1.28%
Insider Trans	0.00%
Inst Own	103.95%
Inst Trans	-1.41%
ROA	23.53%
ROE	36.68%
ROIC	23.78%
Gross Margin	69.98%
Oper. Margin	35.83%
Profit Margin	78.72%
SMA20	1.82%
SMA50	1.39%
SMA200	-2.52%
Trades

Shs Outstand	72.64M
Shs Float	71.32M
Short Float	9.60%
Short Ratio	8.82
Short Interest	6.85M
52W High	25.15 -15.37%
52W Low	17.12 24.30%
Volatility	3.00% 2.46%
ATR (14)	0.49
RSI (14)	54.77
Beta	0.38
Rel Volume	0.63
Avg Volume	775.88K
Volume	487,254

Perf Week	2.60%
Perf Month	1.14%
Perf Quarter	-0.70%
Perf Half Y	-9.87%
Perf YTD	6.45%
Perf Year	23.65%
Perf 3Y	65.73%
Perf 5Y	28.89%
Perf 10Y	108.83%
Recom	1.80
Target Price	35.00
Prev Close	21.08
Price	21.28
Change %	0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-26	Resumed	Oppenheimer	Outperform	$35
Feb-17-26	Initiated	BTIG Research	Buy	$35
Sep-30-25	Initiated	Goldman	Sell	$17
Aug-11-25	Initiated	Oppenheimer	Outperform	$45
Jul-14-25	Initiated	H.C. Wainwright	Buy	$40
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight	$26
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$55
Jun-18-24	Initiated	Cantor Fitzgerald	Overweight
Jul-20-22	Initiated	Goldman	Neutral	$16
Nov-20-17	Initiated	Deutsche Bank	Hold	$13

Oct-19-26 08:00AM	Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026 (Business Wire)
Sep-30-26 02:10PM	Oppenheimer Sees Massive Upside in 2 Stocks (GuruFocus.com)
Sep-02-26 08:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-26 04:05PM	Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO, ZEVTERA and NUZOLVENCE Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award (Business Wire)
Aug-05-26 05:59PM	Innoviva: Q2 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress (Business Wire)
Jun-18-26 08:00AM	Nortiva Bio Launches to Develop Long-Acting Oral Medicines (Business Wire)
Jun-16-26 08:00AM	Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddys for XACDURO in Select International Markets (Business Wire)
Jun-01-26 11:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
May-06-26 05:43PM	Innoviva: Q1 Earnings Snapshot (Associated Press)
04:05PM	Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress (Business Wire)
Mar-01-26 04:27AM	Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 - Here's Why (Insider Monkey)
Feb-28-26 08:26AM	Innoviva, Inc. (INVA): A Bull Case Theory (Insider Monkey)
06:45AM	Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference (MarketBeat)
Feb-26-26 01:48PM	Celldex Therapeutics Stock Earns 88 RS Rating (Investor's Business Daily)
08:17PM	Loading…
Feb-25-26 08:17PM	Nurix Therapeutics Stock Sees RS Rating Jump To 82 (Investor's Business Daily)
05:08PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Feb-19-26 08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive)
08:00AM	Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-18-26 09:17AM	Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains? (Zacks)
Feb-04-26 07:55AM	Eli Lilly (LLY) Q4 Earnings and Revenues Beat Estimates (Zacks)
Jan-08-26 08:23AM	Biotech Is Heating Up-These 2 Red-Hot Stocks Stand Out (MarketBeat)
Dec-21-25 09:57AM	H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating (Insider Monkey)
Dec-12-25 04:56PM	U.S. FDA Approves NUZOLVENCE (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents (Business Wire)
Dec-11-25 06:35PM	Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea (Business Wire)
Nov-25-25 07:00AM	Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-25 04:47AM	Beacon Biosignals secures $86m to advance AI-driven brain biomarker use (Medical Device Network)
06:40PM	Loading…
Nov-05-25 06:40PM	Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates (Zacks) +12.89%
05:33PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Nov-04-25 08:00AM	Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-31-25 09:00AM	AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-30-25 07:55AM	Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-23-25 05:02AM	Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength? (Zacks)
Oct-21-25 08:00AM	Antheia Appoints Eric d'Esparbes as Chief Financial Officer (PR Newswire)
Oct-20-25 08:00AM	Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 (Business Wire)
Oct-14-25 07:30AM	Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-10-25 06:21AM	New Strong Buy Stocks for October 10th (Zacks)
Oct-07-25 09:40AM	Are Investors Undervaluing Innoviva (INVA) Right Now? (Zacks)
08:00AM	Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 (Business Wire)
Sep-17-25 02:27PM	Where is Innoviva (INVA) Headed According to Analysts? (Insider Monkey)
Aug-26-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 08:00AM	Innoviva Specialty Therapeutics Antimicrobial Therapies ZEVTERA and XACDURO Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award (Business Wire)
Aug-12-25 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update (PR Newswire)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly) +7.14%
Aug-06-25 05:06PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Jun-12-25 07:00AM	FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 (Business Wire)
Jun-10-25 06:00AM	Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults (Business Wire)
Jun-03-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
May-20-25 06:00AM	ZEVTERA (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections (Business Wire)
May-08-25 08:54AM	Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling (Insider Monkey)
May-07-25 05:52PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Apr-11-25 12:30AM	Harbor Health Care ETF Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 06:17PM	WEX, Lamb Weston, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-12-25 05:08PM	Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PR Newswire)
Mar-05-25 07:00AM	Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference (Business Wire)
Feb-26-25 04:35PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:04PM	Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-06-25 07:00AM	Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-17-24 07:25AM	Innoviva enters distribution, license agreement with Basilea for Zevtera (TipRanks)
Dec-16-24 07:00AM	Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera (ceftobiprole) (Business Wire)
01:15AM	Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States (GlobeNewswire)
Nov-26-24 07:00AM	Innoviva to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-21-24 11:14PM	Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity (PR Newswire)
Nov-12-24 04:05PM	Innoviva to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-06-24 05:23PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Sep-04-24 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 10:54PM	INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:51PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Jul-09-24 01:30PM	The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 (InvestorPlace)
Jun-27-24 08:00AM	3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge (InvestorPlace)
Jun-18-24 09:51AM	Apple downgraded, Kroger upgraded: Wall Street's top analyst calls (The Fly)
Jun-03-24 07:00AM	Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-31-24 07:30AM	3 Under-$20 Stocks That Could Make You a Fortune (InvestorPlace)
May-20-24 04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
May-10-24 02:04PM	Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis (GuruFocus.com)
May-08-24 10:57PM	INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:09PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
07:00AM	Innoviva to Participate in the BofA Securities Health Care Conference (Business Wire)
Apr-24-24 07:00AM	Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 (Business Wire)
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire)
Feb-29-24 04:56PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:37PM	Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-14-24 02:44AM	Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition (GuruFocus.com)
Jan-10-24 06:16PM	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names (InvestorPlace)
Nov-18-23 07:03AM	Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc (GuruFocus.com)
Nov-03-23 06:00AM	Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million (GuruFocus.com)
Nov-01-23 05:32PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance) +6.92%
04:15PM	Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
04:05PM	Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea (Business Wire)

Show Previous News

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

CEO & DirectorMr. Pavel Raifeld C.F.A.

Chief Financial OfficerMr. Stephen Basso M.B.A.

Chief Accounting Officer & SecretaryMs. Marianne Zhen CPA

Chief Commercial Officer-Innoviva Specialty TherapeuticsMs. Patricia M. Drake

MPADr. David Altarac M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INVA

Innoviva Inc

Upgrade your Finviz experience